MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets

Hangzhou MindRank Technology Co., Ltd. and Suzhou BoomRay Pharma Co., Ltd. announced a strategic collaboration to jointly develop AI‑driven radioligand conjugate (RDC) drugs that use cyclic peptides as targeting ligands, addressing unmet needs in precision oncology diagnostics and therapeutics and…

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.